Aclarion Inc. (Nasdaq: ACON, ACONW), the healthcare technology company based in Broomfield, plans expand Nociscan access across key markets in New York and New Jersey. This expansion builds on previously established Nociscan sites with RadNet affiliates in both states and is driven by the increased availability of MR Spectroscopy (MRS) and enhanced remote operations capabilities within RadNet to meet growing market demand for Nociscan.
“Expanding scanner access is a key element of our strategy to drive Nociscan to standard of care for patients with chronic low back pain,” said Brent Ness, CEO of Aclarion. “The additional sites RadNet is onboarding will help us enable more convenient access to grow scan volume in response to physician demand. It also underscores our strong relationship with this important national imaging provider.”
Lenox Hill Radiology (LHR) operates outpatient imaging centers located in the metropolitan New York area, with 79 total locations throughout New York state. LHR Park Avenue, a flagship site, initially adopted Nociscan to provide access to leading spine physicians in private practice and from organizations such as Weill Cornell. New Jersey Imaging Network (NJIN) is one of the largest imaging providers in NJ with 33 locations. NJIN-Union, in metro NJ, was the first site in NJ to adopt Nociscan to support local physicians and out-of-market referrals through the convenience of Newark Liberty International Airport and Teterboro Airport.
Chronic low back pain (cLBP) is a global healthcare issue, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain, according to Aclarion. Aclarion’s Nociscan solution is an evidence-supported SaaS platform to help physicians identify painful and nonpainful discs in the lumbar spine noninvasively. Nociscan objectively quantifies chemical biomarkers associated with disc pain. When used with other diagnostic tools, Nociscan provides insights into the location of a patient’s low back pain and demonstrates a 97% surgical success rate when all Nociscan-identified pain positive discs are treated.
